Bertilimumab  (Synonyms: CAT 213; iCo-008)

Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research^[1].

Bertilimumab (CAT 213) 中和 eotaxin-1 导致细胞内钙信号传导增加（IC₅₀ 值为 2.86 nM）、表达 CCR3 的 L1.2 细胞迁移（具有 IC₅₀ 值为 0.48 nM)，在体外抑制 eotaxin-1 诱发的人嗜酸性粒细胞形状变化（IC₅₀ 为 0.71 nM）^{[1 ]}。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Bertilimumab (CAT 213) (0.01-10 mg/kg) 静脉内给药 i.po 前 30 分钟 注射人 eotaxin1 (1 μg) 在 IL-5 处理的卵白蛋白致敏小鼠中引起显着的剂量依赖性嗜酸性粒细胞募集抑制。Bertilimumab 还显着抑制中性粒细胞和单核细胞流入气囊，从而导致总细胞流入的剂量相关抑制^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

375348-49-5

柏替木单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sarah Main, et al. A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy. J Pharmacol Exp Ther. 2006 Dec;319(3):1395-404.  [Content Brief]